Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:1
članak: 2 od 5  
Back povratak na rezultate
Srpski arhiv za celokupno lekarstvo
2019, vol. 147, br. 7-8, str. 416-421
jezik rada: engleski
vrsta rada: originalan članak
objavljeno: 15/08/2019
doi: 10.2298/SARH180212048N
Procena kardiovaskularnih faktora rizika kod osoba sa smanjenom tolerancijom na glukozu
aUniverzitet u Prištini sa privremenim sedištem u Kosovskoj Mitrovici, Medicinski fakultet + Priština Clinical-Hospital Center, Gračanica
bUniverzitet u Prištini sa privremenim sedištem u Kosovskoj Mitrovici, Medicinski fakultet

e-adresa: novakovictanja65@gmail.com

Sažetak

Uvod/Cilj Cilj studije je bio da se utvrdi koji su kardiovaskularni faktori rizika prisutni kod osoba sa smanjenom tolerancijom na glukozu (STG) u poređenju sa osobama sa povišenom glikemijom našte (PGN). Metode U studiju je bilo uključeno ukupno 222 odrasla ispitanika sa konstantnim nalazom koncentracije glukoze u rasponu 5,6-6,9 mmol/L. STG je stanje u kojem glukoza u krvi dostiže nivo 7,8-11,1 mmol/L u drugom satu posle primene 75 g u oralnom testu tolerancije na glukozu. PGN je metaboličko stanje između normalne i oštećene tolerancije na glukozu, pri čemu nivoi glukoze našte iznose 5,6-6,9 mmol/L, i sa normalnim vrednostima oralnog testa tolerancije na glukozu. Grupu sa STG su činila 142 ispitanika (107 žena i 35 muškaraca; prosečne starosti 54 ± 13 godina) kod kojih je oralnim testom tolerancije na glukozu utvrđena STG. Ostalih 80 ispitanika (56 žena i 24 muškarca, p = 0,329; prosečne starosti 53 ± 13 godina, p = 0,76) činilo je grupu sa PGN. Kod svih ispitanika analizirani su sledeći parametri: indeks telesne mase (ITM), obim struka, vrednosti krvnog pritiska, glikemije našte, bazalna insulinemija, HOMA-IR (homeostazni model procene insulinske rezistencije), C-reaktivni protein (CRP), fibrinogen i lipidni status. Rezultati Ispitanici u grupi sa STG bili su gojazniji nego oni u grupi sa PGN (ITM: 30,8 ± 5,5 kg/m2 prema 26,72 ± 3,83 kg/m2; p < 0,001), sa većim obimom struka (111 ± 12 cm prema 101 ± 6 cm; p < 0,001). Koncentracije glukoze (6,02 ± 0,75 mmol/L prema 5,80 ± 0,62 mmol/L; p < 0,001) i insulina u krvi (21,61 ± 3,46 prema 6,00 ± 2,80 mIU/L; p < 0,001), kao i vrednosti HOMA-IR (5,78 ± 2,68 prema 1,54 ± 1,46; p < 0,001), takođe su bile više u grupi sa STG. Srednje vrednosti HbA1c kod ispitanika sa STG bile su veće u poređenju sa osobama sa PGN, ali nije bilo statistički značajne razlike (6,21 ± 0,75 prema 5,92 ± 0,43%, p = 0,105). Srednji nivoi visoko osetljivog CRP u grupi sa STG bili su veći u poređenju sa grupom sa PGN (6,70 ± 4,88 mg/L prema 5,83 ± 6,47 mg/L), ali bez statistički značajne razlike (p = 0,76). Zaključak Naša studija ukazuje na prisustvo velikog broja kardiovaskularnih faktora rizika u obe grupe. Dodatno, potvrđeno je da su gojaznost, hiperinsulinemija, hiperholesterolemija, hipertrigliceridemija, viši dijastolni krvni pritisak, kao i sedentarni način života, statistički značajno češće zastupljeni kod bolesnika sa STG.

Ključne reči

cmanjena tolerancija na glukozu; povišena glukoza našte; kardiovaskularni faktori rizika; dijabetes melitus

Reference

*** Helsinki Declaration, which was adopted in 1964 and supplemented on several occasions in 1975, 1983, 1989, 1996, 2000 and 2006. The text of the Declaration available from: http//www. wma.net/en/30publications/10policies/b3/from 15:01 2012th
Abdul-Ghani, M.A., Williams, K., Defronzo, R., Stern, M. (2006) Risk of Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose and Fasting Plasma Glucose. Diabetes Care, 29(7): 1613-1618
American Diabetes Association (2016) Strategies for improving care: Standards of Medical Care in Diabetes 2016. Diabetes Care, Sec. 1, 39(1):6-12
American Diabetes Association (2017) Classification and Diagnosis of Diabetes. Diabetes Care, 40(Supplement 1): S11-S24
Brannick, B., Wynn, A., Dagogo-Jack, S. (2016) Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Experimental Biology and Medicine (Maywood), 241(12): 1323-1331
Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., Butler, P.C. (2003) Cell Deficit and Increased -Cell Apoptosis in Humans with Type 2 Diabetes. Diabetes, 52(1): 102-110
Buysschaert, M., Medina, J.L., Buysschaert, B., Bergman, M. (2016) Definitions (and Current Controversies) of Diabetes and Prediabetes. Current Diabetes Reviews, 12(1): 8-13
Catapano, A.L., Graham, I., de Backer, G., Wiklund, O., Chapman, M., Drexel, H.J., Hoes, A.W., Jennings, C.S., Landmesser, U., Pedersen, T.R., Reiner, Ž., Riccardi, G., Taskinen, M., Tokgozoglu, L. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Kardiol Pol, 253: 281-344
Ewing, J.A. (1984) Detecting alcoholism. The CAGE questionnaire. JAMA, 252(14): 1905
Ferrannini, E., Gastaldelli, A., Iozzo, P. (2011) Pathophysiology of Prediabetes. Medical Clinics of North America, 95(2): 327-339
Garcia-Alcala, H., Soto, V.E., Genestier, T.C.N., Salinas, P.J.L., Hirales, T.O. (2012) Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, Mexico. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 5: 403-403
Garvey, T.W., Mechanick, J.I., Brett, E.M., Garber, A.J., Hurley, D.L., Jastreboff, A.M., Nadolsky, K., Pessah-Pollack, R., Plodkowski, R. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity executive summary. Endocrine Practice, 22(7): 842-884
Ghani, A.M., Defronzo, R.A., Jayyousi, A. (2016) Prediabetes and risk of diabetes and associated complications: Impaired fasting glucose versus impaired glucose tolerance: Does it matter?. Curr Opin Clin Nutr Metab Care, 19(5): 394-403
Gosmanov, A.R., Wan, J. (2014) Low Positive Predictive Value of Hemoglobin A1c for Diagnosis of Prediabetes in Clinical Practice. American Journal of the Medical Sciences, 348(3): 191-194
Grøntved, A., Koivula, R.W., Johansson, I., Wennberg, P., Østergaard, L., Hallmans, G., Renström, F., Franks, P.W. (2016) Bicycling to Work and Primordial Prevention of Cardiovascular Risk: A Cohort Study Among Swedish Men and Women. Journal of the American Heart Association, 5(11): 4413-4413
Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., et al. (2005) Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112(17): 2735-2752
Grundy, S.M. (2012) Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. Journal of the American College of Cardiology, 59(7): 635-643
Gurudevan, S., Garg, P., Malik, S., Khattar, R., Saremi, F., Hecht, H., Demaria, A., Narula, J. (2016) Impaired fasting glucose is associated with increased severity of subclinical coronary artery disease compared to patients with diabetes and normal fasting glucose: Evaluation by coronary computed tomographic angiography. BMJ Open, 6(8): e005148-e005148
Ishola, A.F., Gerstein, H.C., Engert, J.C., Mohan, V., Diaz, R., Anand, S.S., Meyre, D. (2016) Longitudinal relationships between glycemic status and body mass index in a multiethnic study: Evidence from observational and genetic epidemiology. Scientific Reports, 6(1): 30744-30744
Keith, R.J., Al, R.M., Carruba, C., de Jarnett, N., McEvoy, J.W., Bhatnagar, A.W., Blaha, M.J., Defilippis, A.P. (2016) Tobacco Use, Insulin Resistance, and Risk of Type 2 Diabetes: Results from the Multi-Ethnic Study of Atherosclerosis. PLoS One, 11(6): e0157592-e0157592
Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Nathan, D.M., Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346(6): 393-403
Lyssenko, V., Laakso, M. (2013) Genetic Screening for the Risk of Type 2 Diabetes: Worthless or valuable?. Diabetes Care, 36(Supplement_2): S120-S126
Mainous, A.G., Tanner, R.J., Baker, R., Zayas, C.E., Harle, C.A. (2014) Prevalence of prediabetes in England from 2003 to 2011: Population-based, cross-sectional study. BMJ Open, 4(6): e005002-e005002
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7): 412-419
Melmed, S., Polonsky, K.S., Larsen, P.R., Kronenberg, H.M. (2011) Williams Textbook of Endocrinology. Philadelphia: Elsevier Saunders, 12th ed
National Institutes of Health (NIH) (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Obes Res, 6 Suppl 2: 51S-209S
Rasmussen, S.S., Glümer, C., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K. (2008) Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. Diabetologia, 51(2): 249-257
Ridker, P.M. (2003) Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. Circulation, 107(3): 363-369
Sabanayagam, C., Shankar, A., Lee, J., Wong, T.Y., Tai, E.S. (2013) Serum C-reactive protein level and prehypertension in two Asian populations. Journal of Human Hypertension, 27(4): 231-236
Sowers, J.R. (2013) Diabetes Mellitus and Vascular Disease. Hypertension, 61(5): 943-947
Stevens, J., Erber-Oakkar, E., Cui, Z., Cai, J., Virani, S.S., di Angelantonio, E., Wormser, D. (2016) Cardiovascular disease risk by assigned treatment using the 2013 and 1998 obesity guidelines. Obesity (Silver Spring), 24(7): 1554-1560
Williams, B., Mancia, G., Spiering, W., Agabiti, R.E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M. (2018) 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 36(12): 2284-2309
World Health Organization (2010) Global recommendations on physical activity for health. Geneva, Switzerland
World Health Organization (WHO) (2008) Waist circumference and Waist-hip ratio: Report of a WHO Expert Consultation. Geneva, Switzerland
Yue, J., Mao, X., Xu, K., Lü, L., Liu, S., Chen, F., Wang, J.F. (2016) Prevalence, Awareness, Treatment and Control of Diabetes Mellitus in a Chinese Population. PLoS One, 11(4): e0153791-e0153791